Related Experiment Video
Updated: May 23, 2026
Model of Ischemia and Reperfusion Injury in Rabbits
Published on: November 3, 2023
Cardioprotection from ischemia/reperfusion injury: basic and translational research
1Department of Cardiovascular Medicine, Osaka University Graduate School of Medicine, 2-2 Yamada-oka, Suita 565-0871, Japan. minamino@cardiology.med.osaka-u.ac.jp
Insights
Ischemic conditioning, including preconditioning and postconditioning, protects the heart from injury. Pharmacological approaches mimicking these effects offer novel therapeutic strategies for ischemic heart diseases.
Area of Science:
- Cardiology
- Cardiovascular Research
- Translational Medicine
Background:
- Ischemic heart diseases (IHDs) are a leading cause of mortality and heart failure.
- Ischemia-reperfusion injury significantly contributes to adverse outcomes in IHDs.
- Current therapeutic strategies for IHDs require novel approaches to improve patient outcomes.
Purpose of the Study:
- To review the mechanisms underlying ischemic conditioning (preconditioning, postconditioning, remote conditioning).
- To explore the translational potential of pharmacological agents that mimic ischemic conditioning.
- To discuss the future clinical trial requirements for validating these therapeutic strategies.
Main Methods:
- Review of existing literature on ischemic conditioning mechanisms and translational studies.
- Analysis of signaling pathways, autacoids, cytokines, and mitochondrial modulation involved.
- Evaluation of proof-of-concept studies for pharmacological interventions.
Main Results:
- Ischemic conditioning (preconditioning, postconditioning, remote) demonstrably reduces ischemia-reperfusion injury and infarct size.
- Key molecular mediators including autacoids, cytokines, and kinase pathways are identified.
- Pharmacological modifications of these pathways show promise in mimicking cardioprotection.
Conclusions:
- Ischemic conditioning offers a promising cardioprotective strategy for IHDs.
- Pharmacological mimicry of ischemic conditioning presents a novel therapeutic avenue.
- Large-scale clinical trials are essential to confirm the efficacy of these approaches in improving patient outcomes.
Abstract:
Because ischemic heart diseases (IHDs) are a major cause of mortality and heart failure, novel therapeutic approaches are expected to improve the clinical outcomes of patients with IHDs such as acute myocardial infarction and ischemic heart failure. Brief episodes of nonlethal ischemia and reperfusion before sustained ischemia or at the onset of reperfusion can reduce ischemia-reperfusion injury. These ischemic conditioning phenomena are termed "ischemic preconditioning" and "ischemic postconditioning", respectively. Furthermore, brief episodes of nonlethal ischemia and reperfusion applied to the organ or tissue distal to the heart reduce myocardial infarct size, known as "remote ischemic conditioning". The cardioprotection afforded by these ischemic conditionings can be used to treat patients with acute myocardial infarction or cardiac operations. Extensive research has determined that autacoids (eg, adenosine, bradykinin opioid) and cytokines, their respective receptors, kinase signaling pathways and mitochondrial modulation are involved in ischemic conditioning. Modification of these factors by pharmacological agents mimics the cardioprotection by ischemic conditioning and provides a novel therapeutic intervention for IHDs. Here, the potential mechanisms of ischemic conditioning and its "proof-of-concept" translational studies are reviewed. In the near future, large, multicenter, randomized, placebo-controlled, clinical trials will be required to determine whether pharmacological and ischemic conditioning can improve the clinical outcomes of patients with IHDs.
